Australian Gonococcal Surveillance Programme, 1 January to 31 March 2024
DOI:
https://doi.org/10.33321/cdi.2025.49.001Keywords:
antimicrobial resistance, disease surveillance, gonococcal infection, Neisseria gonorrhoeaeAbstract
The Australian National Neisseria Network (NNN) comprises reference laboratories in each state and territory that report data on antimicrobial susceptibility testing to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The AGSP data are presented quarterly in tabulated form, as well as in the AGSP annual report. This report presents national gonococcal antimicrobial resistance surveillance data from 1 January to 31 March 2024.
Downloads
References
Northern Territory Government Department of Health (NT Health) Centre for Disease Control. Penicillinase-producing Neisseria gonorrhoeae (PPNG) and treatment recommendations for gonorrhoea. Darwin: NT Health; 11 March 2024. [Accessed on 11 July 2024.] Available from: https://health.nt.gov.au/__data/assets/pdf_file/0008/1356146/health-alert-ppng-240311.pdf.
World Health Organization (WHO). Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: WHO; 2012. Available from: https://apps.who.int/iris/handle/10665/44863.
Day M, Pitt R, Mody N, Saunders J, Rai R, Nori A et al. Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022. Euro Surveill. 2022;27(46):2200803. doi: https://doi.org/10.2807%2F1560-7917.ES.2022.27.46.2200803.
Maubaret C, Caméléna F, Mrimèche M, Braille A, Liberge M, Mainardis M et al. Two cases of extensively drug-resistant (XDR) Neisseria gonorrhoeae infection combining ceftriaxone-resistance and high-level azithromycin resistance, France, November 2022 and May 2023. Euro Surveill. 2023;28(37):2300456. doi: https://doi.org/10.2807/1560-7917.ES.2023.28.37.2300456.
Pleininger S, Indra A, Golparian D, Heger F, Schindler S, Jacobsson S et al. Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022. Euro Surveill. 2022;27(24):2200455. doi: https://doi.org/10.2807/1560-7917.ES.2022.27.24.2200455.
Ouk V, Say HL, Virak M, Deng S. Frankson R, McDonald R et al. World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme, Cambodia, 2023. Emerg Infect Dis. 2024;30(7):1493–1495. doi: https://doi.org/10.3201/eid3007.240354.
Lahra MM, Hogan TR, Armstrong BH. Australian Gonococcal Surveillance Programme Annual Report, 2021. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.52.
Lahra MM, Van Hal S, Hogan TR. Australian Gonococcal Surveillance Programme Annual Report, 2022. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.45.
van Hal SJ, Whiley DM, Le T, Ray S, Kundu RL, Kerr E et al. Rapid expansion of Neisseria gonorrhoeae ST7827 clone in Australia, with variable ceftriaxone phenotype unexplained by genotype. J Antimicrob Chemother. 2023;78(9):2203–2208. doi: https://doi.org/10.1093/jac/dkad221.
Unemo M. Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015;15:364. doi: https://doi.org/10.1186/s12879-015-1029-2.
Ong JJ, Bourne C, Dean JA, Ryder N, Cornelisse VJ, Murray S et al. Australian sexually transmitted infection (STI) management guidelines for use in primary care, 2022 update. Sexual Health. 2023;20(1):1–8. doi: https://doi.org/10.1071/SH22134.
Published
How to Cite
License
Copyright (c) 2025 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
